When chemotherapy stops working, patients and their care teams are left with few options. For people with poorly differentiated neuroendocrine carcinoma, that moment comes too
By Anne-Marie Green Director of Communications, NETRF Based in Columbus, Ohio, Tawnisha Jones has spent 11 years as a senior outpatient coder at the Ohio
Elyse Gellerman, MHS, NETRF CEO When neuroendocrine cancer advocates from around the world gather, there’s tremendous energy and commitment to serving the needs of patients
By Anna C. Greene, PhD, NETRF Chief Scientific Officer The language used to describe neuroendocrine cancer is complex, and it is not always used consistently.
By Anna C. Greene, PhD, NETRF Chief Scientific Officer People with neuroendocrine tumors (NETs) often ask why the same treatment can work very well for
The FDA has approved lutetium Lu-177 dotatate injection (Bexlutry), a new option for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Bexlutry is a radioligand
CDH17 Remains a Promising Target, Even as the CHM CDH17 Trial Changes Course The CHM CDH17 clinical trial, a CAR T-cell therapy built on research
The Neuroendocrine Tumor Research Foundation (NETRF) is deeply grateful to Citizens of Humanity for donating $28,000 through the sale of The Lindz, a jean created
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Same organ, different disease Words matter in cancer, especially when the name of an organ becomes
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Why do some neuroendocrine tumors grow slowly for years, while others progress more quickly? Researchers have